Literature DB >> 15349708

A new opportunity for thalidomide? Further randomised controlled trial are necessary.

Federico Marchetti, Marzia Lazzerini, Alessandro Ventura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15349708     DOI： 10.1007/s00228-004-0819-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  Intestinal involvement in children with Behçet's disease.

Authors:  Federico Marchetti; Chiara Trevisiol; Alessandro Ventura
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

Review 2.  Thalidomide: a review of approved and investigational uses.

Authors:  S James Matthews; Christopher McCoy
Journal:  Clin Ther       Date:  2003-02       Impact factor: 3.393

Review 3.  Two decades of orphan product development.

Authors:  Marlene E Haffner; Janet Whitley; Marie Moses
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

4.  Thalidomide in Crohn disease and the risk of peripheral neuropathy.

Authors:  M Ahmed; S El-Hadi; H R Jenkins
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-10       Impact factor: 2.839

5.  Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

Authors:  S Facchini; M Candusso; S Martelossi; M Liubich; E Panfili; A Ventura
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-02       Impact factor: 2.839

6.  S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide.

Authors:  J B Zeldis; B A Williams; S D Thomas; M E Elsayed
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

Review 7.  Thalidomide use in pediatric patients.

Authors:  Olga Bessmertny; Trinh Pham
Journal:  Ann Pharmacother       Date:  2002-03       Impact factor: 3.154

8.  Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century.

Authors:  G J Annas; S Elias
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

Review 9.  Thalidomide.

Authors:  Michael E Franks; Gordon R Macpherson; William D Figg
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

Review 10.  Optimizing anti-TNF treatment in inflammatory bowel disease.

Authors:  Paul Rutgeerts; Gert Van Assche; Séverine Vermeire
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.